142 related articles for article (PubMed ID: 12467306)
21. Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats.
Lu H; Wang JJ; Chan KK; Young D
Drug Metab Dispos; 1998 May; 26(5):476-82. PubMed ID: 9571229
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
23. The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma.
Hassan M; Nilsson C; Olsson H; Lundin J; Osterborg A
Eur J Haematol; 1999 Sep; 63(3):163-70. PubMed ID: 10485271
[TBL] [Abstract][Full Text] [Related]
24. Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine.
Kaijser GP; Beijnen JH; Bult A; Keizer HJ; Underberg WJ
J Chromatogr B Biomed Sci Appl; 1997 Mar; 690(1-2):131-8. PubMed ID: 9106037
[TBL] [Abstract][Full Text] [Related]
25. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies.
Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A
Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071
[TBL] [Abstract][Full Text] [Related]
26. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
Lokiec F; Santoni J; Weill S; Tubiana-Hulin M
Anticancer Drugs; 1996 Nov; 7(8):893-6. PubMed ID: 8991196
[TBL] [Abstract][Full Text] [Related]
27. Comparative activity of ifosfamide and cyclophosphamide.
Brade W; Seeber S; Herdrich K
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S1-9. PubMed ID: 3545522
[TBL] [Abstract][Full Text] [Related]
28. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
29. Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma.
Gunsilius E; Gierlich T; Mross K; Gastl G; Unger C
Cancer Invest; 2001; 19(8):808-11. PubMed ID: 11768034
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M
Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104
[TBL] [Abstract][Full Text] [Related]
31. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Kerbusch T; Mathôt RA; Keizer HJ; Kaijser GP; Schellens JH; Beijnen JH
Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
Boddy AV; Proctor M; Simmonds D; Lind MJ; Idle JR
Eur J Cancer; 1995; 31A(1):69-76. PubMed ID: 7695982
[TBL] [Abstract][Full Text] [Related]
33. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo.
Brain EG; Yu LJ; Gustafsson K; Drewes P; Waxman DJ
Br J Cancer; 1998 Jun; 77(11):1768-76. PubMed ID: 9667645
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Kerbusch T; vanPutten JW; Groen HJ; Huitema AD; Mathĵt RA; Beijnen JH
Cancer Chemother Pharmacol; 2001 Jul; 48(1):53-61. PubMed ID: 11488525
[TBL] [Abstract][Full Text] [Related]
35. Renal clearance of ifosfamide.
Springate J; Zamlauski-Tucker MJ; Lu H; Chan KK
Drug Metab Dispos; 1997 Sep; 25(9):1081-2. PubMed ID: 9311624
[TBL] [Abstract][Full Text] [Related]
36. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
[TBL] [Abstract][Full Text] [Related]
37. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
38. [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
Sloderbach A; Górska A; Sikorska M; Misiura K; Hładoń B
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1235-53. PubMed ID: 24379264
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacokinetics of cyclophosphamide.
de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
Clin Pharmacokinet; 2005; 44(11):1135-64. PubMed ID: 16231966
[TBL] [Abstract][Full Text] [Related]
40. Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer.
Wagner A; Hempel G; Boos J
Anticancer Drugs; 1997 Jun; 8(5):419-31. PubMed ID: 9215603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
